US Remains Top Investment Destination for Pharmaceuticals, GSK Chief Confirms Amid UK Industry Exodus

GSK Commits $30 Billion to US Market Despite UK Roots

The United States is the best place for pharmaceutical investment, according to Dame Emma Walmsley, chief executive of GSK, one of the UK’s largest vaccines and medicines companies.

Dame Emma announced that GSK will invest $30 billion (£23 billion) in the US by 2030, reinforcing America’s position as the global leader in pharmaceutical innovation and business development.

The statement comes as multiple major drug makers have abandoned UK projects worth billions of pounds following years of frustration over NHS drug budgets and mounting pressure from President Donald Trump to establish US-based production facilities.

Major Pharmaceutical Companies Pull Back from UK Investments

Several industry giants have recently scaled back their British operations:

Merck (MSD in Europe) scrapped a planned £1 billion expansion of its UK operations
AstraZeneca paused a £200 million investment in a Cambridge research facility while committing tens of billions of dollars to US projects
Multiple other drug companies have expressed minimal interest in UK investments despite successive governments promoting Britain as a life sciences superpower

New UK-US Trade Deal Eliminates Pharmaceutical Tariffs

Despite the challenging investment climate, Dame Emma, who will leave GSK in January after eight years as chief executive, welcomed a recent trade agreement between the UK and US.

The deal ensures zero tariffs on UK pharmaceutical shipments to America in exchange for the NHS paying higher prices for medicines. The tariff-free arrangement is guaranteed for three years.

Speaking from GSK’s central London headquarters, Dame Emma called the agreement “a step in the right direction” for Britain. She said it reverses a long-term decline in the portion of NHS budgets allocated to medicines compared to other countries’ health systems.

Why the US Leads Global Pharmaceutical Investment

Dame Emma said she would not “shy away” from GSK’s US investment plans, where the company generates more than half of its revenue.

“The US is still the leading market in the world in terms of the launches of new drugs and vaccines,” she explained. Alongside China, America represents “the best market in the world to do business development,” she added.

GSK Breakthrough Treatment Could Transform Asthma Care

The increased NHS spending could encourage innovation like GSK’s new asthma drug, which can be taken twice yearly and could reduce hospital admissions by 70% for serious asthma sufferers.

GSK expects NHS approval for the treatment within weeks.

UK Health Outcomes Vary Dramatically by Location

Asked about the country’s health challenges, Dame Emma pointed to “social demographic root causes” for declining health outcomes.

“You can probably get a 10 or 15-year difference in lifespan prospects depending on which postcode you’re in,” she said.

Dame Emma identified British diets and inadequate nutrition education as contributing factors. “I think there’s no question that the food system is fundamentally something we need to look at harder,” she stated.

NHS vs. US Healthcare: A CEO’s Personal Perspective

Dame Emma shared her personal experiences with both healthcare systems, having given birth in London, Paris, and twice in New York.

“Both the experience of childbirth and all the follow up that happens afterwards are very, very different,” she said, noting differences in medical advice, visit frequency, hospital stay duration, and follow-up care.

She emphasized that what matters most is balancing price, access, and outcomes, adding that the NHS still has “work to do” on achieving the right balance.

AI Promises to Accelerate Pharmaceutical Innovation

Dame Emma, who also serves on Microsoft’s board, said the world is approaching major advances in health science thanks to artificial intelligence developments that could accelerate drug discovery.

“90% of the projects in our industry don’t work, they take a decade and cost billions,” she explained. “Getting to a place where instead of 10% working, 20% working will completely change the trajectory of innovation.”

She concluded by emphasizing healthcare’s universal importance: “It is one of the few things that every single person on the planet ends up caring about.”

Key Takeaways: